Previous 10 | Next 10 |
PRINCETON, N.J. , Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief S...
PRINCETON, N.J. , Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has ap...
Soligenix ( SNGX ) announced appointment of Jonathan Guarino, as its Senior Vice President and Chief Financial Officer. More news on: Soligenix, Inc., Healthcare stocks news, Read more ...
PRINCETON, N.J. , Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h...
PRINCETON, N.J. , Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Presid...
DPW Holdings (NYSEMKT: DPW ) +51% on eliminating $2M of debt. More news on: DPW Holdings, Inc., Lannett Company, Inc., Tallgrass Energy, LP, Stocks on the move, Read more ...
Based on a preplanned interim analysis, the independent Data Monitoring Committee (DMC) has recommended that the Phase 3 DOM-INNATE study evaluating Soligenix's (NASDAQ: SNGX ) SGX942 (dusquetide) for the treatment of oral mucositis in head and neck cancer patients receiving ch...
PRINCETON, N.J. , Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has rec...
PRINCETON, N.J. , Aug. 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Nation...
Soligenix (NASDAQ: SNGX ): Q2 GAAP EPS of -$0.12 beats by $0.02 . More news on: Soligenix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK and PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is making significant strides in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...